"Stavudine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.
| Descriptor ID |
D018119
|
| MeSH Number(s) |
D03.383.742.680.705.875 D13.570.230.500.850 D13.570.230.855.875 D13.570.685.705.875
|
| Concept/Terms |
Stavudine- Stavudine
- D4T
- 2',3'-Didehydro-3'-deoxythymidine
- 2',3' Didehydro 3' deoxythymidine
- 2',3'-Didehydro-2',3'-dideoxythmidine
|
Below are MeSH descriptors whose meaning is more general than "Stavudine".
Below are MeSH descriptors whose meaning is more specific than "Stavudine".
This graph shows the total number of publications written about "Stavudine" by people in this website by year, and whether "Stavudine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Stavudine" by people in Profiles.
-
Castelnuovo B, John L, Lutwama F, Ronald A, Spacek LA, Bates M, Kamya MR, Colebunders R. Three-year outcome data of second-line antiretroviral therapy in Ugandan adults: good virological response but high rate of toxicity. J Int Assoc Physicians AIDS Care (Chic). 2009 Jan-Feb; 8(1):52-9.
-
Torriani FJ, Komarow L, Parker RA, Cotter BR, Currier JS, Dubé MP, Fichtenbaum CJ, Gerschenson M, Mitchell CK, Murphy RL, Squires K, Stein JH. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol. 2008 Aug 12; 52(7):569-76.
-
Kamya MR, Mayanja-Kizza H, Kambugu A, Bakeera-Kitaka S, Semitala F, Mwebaze-Songa P, Castelnuovo B, Schaefer P, Spacek LA, Gasasira AF, Katabira E, Colebunders R, Quinn TC, Ronald A, Thomas DL, Kekitiinwa A. Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr. 2007 Oct 01; 46(2):187-93.
-
Sanne I, Piliero P, Squires K, Thiry A, Schnittman S. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr. 2003 Jan 1; 32(1):18-29.